Article Document Information Content Entity Continuant Continuant Entity Entity Review Generically Dependent Continuant 2025-06-24T09:31:00 RDF description of Clinical use of bone turnover markers to monitor pharmacologic fracture prevention therapy [review] - http://repository.healthpartners.com/individual/document-rn19659 Clinical use of bone turnover markers to monitor pharmacologic fracture prevention therapy [review] Drugs and Drug Therapy 11763 public 1 10.1007/s11914-011-0091-y document-rn19659 review Fractures Osteoporosis Bone Density Prevention 10 Current osteoporosis reports <p>Monitoring of drug therapies to prevent fractures is controversial. Measurement of bone turnover markers has the potential to identify those with a suboptimal response to fracture prevention medication within a few months of its commencement. However, given the imprecision of currently commercially available assays of bone turnover markers, many individual persons who are "suboptimal medication responders" are likely to be misclassified as "adequate responders" or vice versa, depending on the cut point chosen to define suboptimal and adequate response. Before bone turnover markers can be recommended for routine use in clinical practice to monitor fracture prevention therapies, three advances are needed: 1) bone marker assays with better precision; 2) research establishing optimal cut points of bone marker levels to distinguish "suboptimal responders" from "adequate responders"; and 3) research establishing the incremental fracture reduction benefit from clinical interventions for "suboptimal responders" identified from bone marker measurements.<p> 18106 Monitoring, Physiologic 2022-02-21T22:48:57.408-06:00